DRAXIN and central nervous system cancer: The above conclusive evidence, combined with the results of the bioinformatics analysis, reveals the role of DRAXIN as a key pathogenic factor in glioma from multiple dimensions, suggesting that DRAXIN can be targeted for intervention to improve the prognosis of glioma patients.